3iQ, CoinShares launch bitcoin ETF on TSX
Apr 19th, 2021 | By James Lord, CFA
3iQ and CoinShares have teamed up to launch a directly backed bitcoin ETF on the Toronto Stock Exchange.
3iQ and CoinShares have teamed up to launch a directly backed bitcoin ETF on the Toronto Stock Exchange.
Horizons ETFs has launched a pair of new funds – the BetaPro Bitcoin ETF (HBIT CN) and BetaPro Inverse Bitcoin ETF (BITI CN) – providing long or short exposure to bitcoin through the use of futures contracts.
CI Global Asset Management has become the third Canadian ETF issuer to launch a directly backed bitcoin ETF.
Evolve Funds has lowered the management fee on its Bitcoin ETF (EBIT CN) just one week after the fund launched on the Toronto Stock Exchange.
AdvisorShares’ actively managed US cannabis ETF has surpassed $1 billion in assets under management, less than six months after its debut on NYSE Arca.
Evolve Funds has become the second Canadian ETF issuer to secure regulatory approval for a directly backed bitcoin ETF.
Purpose Investments looks set to introduce North America’s first directly backed bitcoin ETF following approval by Canadian securities regulators. It will also become the first exchange-traded bitcoin product of any major developed market to officially sport the ‘ETF’ moniker.
ETFs providing exposure to the medical cannabis investment theme appear poised to enter a new stage of growth fuelled by merger and acquisition activity.
Horizons ETFs Canada has slashed the management fee on the Horizons Gold ETF (HUG CN) from 0.65% to 0.20%, making it one of the lowest-cost gold ETFs in Canada. Steve Hawkins, President and CEO of Horizons ETFs, said, “Our fee reduction represents more than a two-thirds decrease in the management fee of the ETF – a significant cost savings opportunity that we are happy to pass on to investors looking for a low-cost ETF solution to obtain exposure to gold.”
Overlooked by many and misunderstood by others, ETFs providing exposure to the medical cannabis industry represent an investment proposition that appears on the cusp of a mainstream breakthrough as fresh medical evidence of the pharmacological and therapeutic benefits of cannabis combines with changing attitudes and pro-legalization momentum worldwide.